Experienced leader will provide commercialization expertise to company
SALT LAKE CITY, Oct. 14 /PRNewswire/ -- Axial Biotech, Inc., a company revolutionizing spine care through the development of molecular diagnostic technologies, announced today the appointment of William L. Lister as the newest member of the Board of Directors. Lister will serve on the board's Compensation Committee and will focus on guiding the company in the commercialization of new molecular assays.
"I am excited about Axial Biotech's potential to dramatically change the detection and treatment of many spinal disorders. The Company's first product, called ScoliScore(TM), is a prognostic assay that will identify the likelihood for spinal curve progression," stated Lister. "This product has the opportunity to greatly benefit children diagnosed with this crippling disease."
"The company is very pleased to have Bill join our board as a director," said John Climaco, Axial Biotech's President & CEO. "Bill has a very impressive record in the diagnostics industry of creating and executing major strategies as well as helping companies build the foundation for meaningful and sustained growth. His skills will be instrumental in helping the company achieve its new expansion imperatives."
Lister has had a distinguished career in sales, marketing and several
management positions in the healthcare sector with companies focused in the
diagnostic and pharmaceutical industries. Most recently, Lister was the
Senior Vice President and General Manager of Patient Care at Roche
Diagnostics Corporation. In this position, Lister was responsible for the
U.S. Diabetes Monitoring, Insulin Pump and Point of Care Diagnostics, along
with the Global Drugs of Abuse Business Unit. He was a member of the
Corporation's Management Group, which was responsible for setting policy
and overseeing all U.S. diagnostic and biochemical operations along with
the Global Diabetes Care Operating Committee. In
|SOURCE Axial Biotech, Inc.|
Copyright©2008 PR Newswire.
All rights reserved